Sarepta Therapeutics stock gets new ELEVIDYS data

Published on 10/05/2026 at 16:09 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Sarepta presented new ELEVIDYS data on September 30, while Q2 adjusted EPS reached USD 0.64 against a USD 0.58 consensus estimate. Revenue fell 34 percent year over year.

SRPT, US8036071004, Illustration mit AI erstellt.

Sarepta Therapeutics stock (ISIN US8036071004) was trading at USD 17.45 on Nasdaq on October 5, 2026, at 10:08 a.m. ET, giving the company a market capitalization of USD 1.8 billion. On September 30, Sarepta Therapeutics presented new ELEVIDYS data at the 2026 World Muscle Society Annual Congress, highlighting safety and clinically meaningful functional benefit in older ambulatory patients with Duchenne muscular dystrophy.

ELEVIDYS data meet a weaker sales trend

The data presentation arrives after Sarepta's second-quarter operating picture split into two directions. According to Zacks on September 4, 2026, adjusted EPS for Q2 2026 reached USD 0.64 versus a USD 0.58 consensus estimate, but total revenue fell 34 percent year over year to USD 401.3 million.

The product mix explains the tension. ELEVIDYS revenue was USD 98.1 million in Q2 2026, down 65 percent year over year, while PMO product revenue reached USD 230.6 million and stayed relatively stable year over year, according to Zacks.

Analysts disagree on Sarepta value

The analyst picture is sharply divided. MarketBeat reported on October 5, 2026, that HC Wainwright reiterated a Sell rating with a USD 5.00 price target, while seven analysts rated the stock Buy, seven Hold and seven Sell.

That distribution produces a Hold consensus and an average price target of USD 22.71, according to MarketBeat. Against the USD 17.45 Nasdaq price, the average target is 30.1 percent above the price, while the HC Wainwright target is 71.3 percent below it.

Stock remains near its yearly low

SRPT's October 5 intraday range extended from USD 17.10 to USD 17.50, and the stock was down USD 0.05, or 0.31 percent, from the previous close of USD 17.50. Its 52-week range of USD 14.68 to USD 25.32 places the current price 18.9 percent above the low and 31.1 percent below the high.

For investors, the key contrast is between the clinical signal from ELEVIDYS and the commercial pressure visible in Q2 revenue. Sarepta's 2026 net product revenue guidance stands at USD 1.2 billion to USD 1.3 billion, while collaboration and other revenue guidance was raised to USD 550 million to USD 600 million, according to Zacks.

Nasdaq price holds at USD 17.45

Sarepta Therapeutics stock was last at USD 17.45 on Nasdaq on October 5, 2026, at 10:08 a.m. ET. The next valuation debate centers on whether new ELEVIDYS evidence can offset the 34 percent year-over-year revenue decline reported for Q2 2026.